SPAC144.01 Antibody

What is SPAC144.01 Antibody and what organism does it target?

SPAC144.01 Antibody is a polyclonal antibody raised in rabbits against a recombinant SPAC144.01 protein from Schizosaccharomyces pombe (strain 972/ATCC 24843), also known as fission yeast. The antibody specifically recognizes the SPAC144.01 protein (UniProt accession: Q9UTM1) and is designed for research applications like ELISA and Western blotting. As a non-conjugated antibody provided in liquid form, it contains preservatives (0.03% Proclin 300) and is stored in a buffer of 50% glycerol and 0.01M PBS at pH 7.4. This antibody has been purified using antigen affinity methods to ensure specificity for its target protein .

How should SPAC144.01 Antibody be stored to maintain optimal activity?

SPAC144.01 Antibody should be stored at either -20°C or -80°C upon receipt. Repeated freeze-thaw cycles should be avoided as these can degrade the antibody and reduce its efficacy in experimental applications. The antibody is supplied in a storage buffer containing 50% glycerol, which helps protect the antibody structure during freezing. For short-term use, small aliquots can be prepared to prevent the need for multiple freeze-thaw cycles of the original stock. When handling the antibody, it's advisable to keep it on ice and return it to storage promptly after use to maximize its shelf life and activity in experimental applications .

What are the validated applications for SPAC144.01 Antibody?

The SPAC144.01 Antibody has been validated for enzyme-linked immunosorbent assay (ELISA) and Western blotting (WB) applications. These techniques allow researchers to detect and quantify the SPAC144.01 protein in various experimental contexts. In ELISA, the antibody can be used to detect the target protein in solution, while Western blotting enables visualization of the protein in cell or tissue lysates, providing information about protein expression levels and molecular weight. When designing experiments with this antibody, researchers should consider its polyclonal nature, which means it recognizes multiple epitopes on the target protein, potentially offering higher sensitivity but with some variability between antibody lots .

What controls should be included when using SPAC144.01 Antibody in Western blotting experiments?

When using SPAC144.01 Antibody in Western blotting, several crucial controls should be implemented. First, include a positive control using known samples containing the SPAC144.01 protein from S. pombe strain 972. Second, incorporate a negative control using samples from organisms that don't express the target protein or from knockout strains of S. pombe lacking the SPAC144.01 gene. Third, run a secondary antibody-only control to identify any non-specific binding. Fourth, consider using pre-immune serum as an additional negative control to account for potential native rabbit antibodies that might recognize yeast proteins. When troubleshooting signal issues, adding a loading control antibody (like anti-tubulin) in a separate blot or using a differently colored detection system helps normalize protein loading. Since SPAC144.01 Antibody is polyclonal, optimization of antibody dilution (starting at 1:1000) is essential for balancing specific signal with background .

How should researchers optimize ELISA protocols when using SPAC144.01 Antibody?

Optimizing ELISA protocols with SPAC144.01 Antibody requires systematic adjustment of several parameters. Begin with a titration series (1:500 to 1:10,000) to determine optimal antibody concentration balancing specific signal versus background. Since this antibody targets a yeast protein, consider using special blocking buffers containing 5% BSA rather than milk-based blockers to prevent cross-reactivity. Incubation time and temperature significantly impact results - typically start with 1-2 hours at room temperature or overnight at 4°C for primary antibody binding. For detection systems, HRP-conjugated anti-rabbit secondary antibodies work well, with TMB as a substrate for colorimetric detection. When developing quantitative ELISAs, generate standard curves using purified recombinant SPAC144.01 protein at concentrations ranging from 1-1000 ng/mL. To ensure reproducibility, perform all conditions in triplicate and include inter-assay calibration samples .

What are the recommended dilution ranges for different applications of SPAC144.01 Antibody?

While specific dilutions may require optimization for individual experimental conditions, recommended starting dilution ranges for SPAC144.01 Antibody are as follows: For Western blotting, begin with 1:500 to 1:2000 dilution in 5% BSA in TBST buffer. For ELISA applications, a starting range of 1:1000 to 1:5000 is typically appropriate. If using the antibody for immunoprecipitation, although not specifically validated for this application, a starting concentration of 2-5 μg per 500 μg of total protein lysate could be tried. It's crucial to perform antibody titration experiments to determine the optimal concentration that provides the best signal-to-noise ratio for your specific experimental setup. The optimal dilution may vary depending on the abundance of the target protein, sample preparation methods, detection systems, and even between different lots of the antibody .

What are common causes of false negative results when using SPAC144.01 Antibody, and how can they be addressed?

False negative results with SPAC144.01 Antibody can stem from several causes. Most commonly, insufficient protein denaturation prevents epitope exposure, particularly in Western blotting. To address this, ensure complete denaturation by increasing SDS concentration to 2% in sample buffer and extending boiling time to 10 minutes. Antibody degradation from improper storage can be prevented by maintaining -20°C or -80°C storage and avoiding freeze-thaw cycles. For low-abundance proteins, concentrate samples using immunoprecipitation before analysis and use enhanced chemiluminescence detection systems. Transfer efficiency issues in Western blotting can be improved by optimizing transfer conditions (increasing time or current) and confirming with reversible protein stains like Ponceau S. If the standard antibody incubation (1-2 hours at room temperature) yields no signal, extend to overnight at 4°C with gentle rocking to enhance binding. For recalcitrant samples, consider alternative epitope retrieval methods or different lysis buffers containing appropriate protease inhibitor cocktails .

How can researchers address non-specific binding issues when using SPAC144.01 Antibody?

Non-specific binding with SPAC144.01 Antibody can be systematically reduced through several approaches. First, optimize blocking by testing different blocking agents (5% BSA, 5% non-fat milk, commercial blocking buffers) and extending blocking time to 2 hours at room temperature. Second, increase the stringency of wash steps by adding 0.05-0.1% Tween-20 to wash buffers and extending washing time to 15 minutes with 4-5 changes of buffer. Third, try a more dilute antibody concentration (e.g., 1:2000 to 1:5000) to reduce background while maintaining specific signal. Fourth, pre-absorb the antibody against proteins from organisms similar to but distinct from S. pombe to remove cross-reactive antibodies. Fifth, use higher purity secondary antibodies with minimal cross-reactivity to yeast proteins. For persistent issues, consider further purification of the antibody using antigen-specific affinity columns. The polyclonal nature of this antibody means some batch-to-batch variation in non-specific binding characteristics may occur, so optimization may need to be performed for each new lot .

What modifications to sample preparation protocols can improve detection sensitivity when working with SPAC144.01 Antibody?

Enhancing detection sensitivity with SPAC144.01 Antibody requires optimized sample preparation. First, use specialized yeast lysis buffers containing glass beads and mechanical disruption (vortexing for 5×30 seconds with 30-second cooling intervals) to ensure complete cell breakage. Second, include a comprehensive protease inhibitor cocktail specifically designed for yeast samples to prevent target degradation during extraction. Third, perform protein concentration using TCA precipitation followed by acetone washing to remove interfering compounds. Fourth, enrich for the target protein using subcellular fractionation based on the known localization of SPAC144.01. Fifth, optimize sample loading to 30-50 μg of total protein per well for Western blotting applications. For particularly challenging samples, consider using signal enhancement systems such as biotin-streptavidin amplification. Additionally, increasing the linear range of detection by using fluorescently labeled secondary antibodies and imaging with appropriate instruments can significantly improve sensitivity while maintaining quantitative accuracy .

How should researchers quantify and normalize data from Western blots using SPAC144.01 Antibody?

Accurate quantification and normalization of Western blot data using SPAC144.01 Antibody requires a systematic approach. First, capture images using a digital imaging system with a linear dynamic range (e.g., CCD camera-based systems) rather than film, which has a limited linear range. Second, use densitometry software (ImageJ, Image Lab, etc.) to quantify band intensities, ensuring measurements remain within the linear range of detection. Third, always normalize target protein signals to a loading control such as actin, tubulin, or total protein (measured by Ponceau S or similar stains) from the same sample. For temporal studies, calculate relative expression as a ratio to time zero or control condition samples. When comparing across multiple blots, include a common calibrator sample on each blot to account for inter-blot variability. Statistical analysis should incorporate at least three biological replicates, with appropriate statistical tests applied based on data distribution. Presenting both raw and normalized data in publications is recommended for transparency, along with methodology details including exposure settings and lot number of the antibody used .

What approaches can resolve discrepancies between ELISA and Western blot results using SPAC144.01 Antibody?

Discrepancies between ELISA and Western blot results using SPAC144.01 Antibody often stem from fundamental differences between these techniques. Western blotting detects denatured proteins separated by size, while ELISA typically measures native proteins in solution. To resolve discrepancies, first verify epitope integrity by comparing different protein extraction methods that preserve native versus denatured states. Second, conduct epitope mapping experiments to determine if the antibody recognizes linear (suitable for Western blot) or conformational epitopes (better detected by ELISA). Third, assess for post-translational modifications that may affect antibody binding differently in each method. Fourth, examine for cross-reactivity with related proteins using knockout controls or recombinant protein standards. Fifth, consider the detection threshold differences—ELISA typically offers higher sensitivity (picogram range) versus Western blotting (nanogram range). A structured troubleshooting approach involves creating a validation panel of samples tested in parallel with both methods, applying correlation analysis to identify systematic differences, and potentially using a third orthogonal method (like mass spectrometry) for definitive protein identification .

How can researchers validate the specificity of SPAC144.01 Antibody in their experimental system?

Validating the specificity of SPAC144.01 Antibody requires multiple complementary approaches. First, perform epitope blocking experiments by pre-incubating the antibody with excess recombinant SPAC144.01 protein before application to samples—specific signals should be eliminated. Second, test the antibody against samples from SPAC144.01 knockout strains, which should show no binding if the antibody is specific. Third, use RNA interference to knock down SPAC144.01 expression and demonstrate corresponding reduction in antibody signal intensity. Fourth, compare detection patterns with an alternative antibody targeting a different epitope of the same protein. Fifth, perform immunoprecipitation followed by mass spectrometry to confirm the identity of the captured protein. For advanced validation, expressing tagged versions of SPAC144.01 (e.g., GFP-tagged) and demonstrating co-localization or co-detection with the antibody provides strong evidence of specificity. Documentation of these validation steps is essential for publication, as journal requirements for antibody validation have become increasingly stringent .

How can SPAC144.01 Antibody be adapted for immunofluorescence microscopy in S. pombe research?

Adapting SPAC144.01 Antibody for immunofluorescence microscopy requires specialized protocols for fission yeast cells. Begin with cell wall digestion using lysing enzymes (1 mg/mL) or zymolyase (0.5 mg/mL) in buffer containing 1.2M sorbitol as an osmotic stabilizer for 30-60 minutes at 30°C. Fix cells using either 3.7% formaldehyde for 30 minutes or methanol at -20°C for 6 minutes, depending on epitope sensitivity. For membrane permeabilization, use 0.1% Triton X-100 for 5 minutes, followed by blocking with 5% BSA in PBS for 1 hour. Apply SPAC144.01 Antibody at 1:100 to 1:500 dilution overnight at 4°C, followed by fluorophore-conjugated anti-rabbit secondary antibody (1:500) for 1 hour at room temperature. Counterstain the nucleus with DAPI (1 μg/mL) and mount slides with anti-fade mounting medium. To distinguish specific staining from background, parallel processing of negative controls (pre-immune serum, secondary antibody only, and when available, SPAC144.01 deletion strains) is essential. For co-localization studies, combine with established organelle markers using differentially colored fluorophores .

What considerations are important when using SPAC144.01 Antibody in chromatin immunoprecipitation (ChIP) experiments?

While SPAC144.01 Antibody hasn't been specifically validated for ChIP applications, researchers could adapt it for this purpose with careful optimization. The protocol would require initial crosslinking of S. pombe cells with 1% formaldehyde for 15 minutes, followed by quenching with 125 mM glycine. After cell lysis using glass bead disruption in specialized ChIP lysis buffer, chromatin should be sheared to 200-500 bp fragments using sonication (typically 10-15 cycles of 30 seconds on/30 seconds off). Pre-clear the chromatin with protein A/G beads before immunoprecipitation with 5-10 μg of SPAC144.01 Antibody per sample, incubating overnight at 4°C. Include an IgG control antibody and, ideally, a known ChIP-grade antibody as positive control. After washing with increasingly stringent buffers, reverse crosslinks by heating at 65°C for 4-6 hours, followed by proteinase K and RNase A treatment. Purify DNA using phenol-chloroform extraction or commercial kits before analysis by qPCR or sequencing. Due to the polyclonal nature of this antibody, extensive validation through sequential ChIP with alternative antibodies or tagged protein controls is recommended to confirm specificity .

What emerging technologies might enhance the utility of SPAC144.01 Antibody in S. pombe research?

Emerging technologies offer exciting possibilities for expanding SPAC144.01 Antibody applications. Super-resolution microscopy techniques (STORM, PALM, SIM) could provide unprecedented spatial resolution of SPAC144.01 protein localization within yeast cells, requiring only standard immunofluorescence protocols with high-quality secondary antibodies. Microfluidic-based single-cell Western blotting systems could enable protein quantification in individual yeast cells, though this would require optimization of cell lysis conditions compatible with the microfluidic platform. For temporal studies, live-cell imaging using cell-permeable fluorophore-conjugated antibody fragments (Fabs) derived from SPAC144.01 Antibody could track protein dynamics, though this would require additional antibody engineering. Mass cytometry (CyTOF) using metal-tagged SPAC144.01 Antibody could allow simultaneous measurement of multiple proteins without fluorescence spectral overlap limitations. Finally, integrating SPAC144.01 Antibody with CRISPR-based proximity labeling systems could map protein-protein interactions with spatial and temporal resolution, providing insights into the functional role of SPAC144.01 in fission yeast biology .

What considerations are important when repurposing SPAC144.01 Antibody for screening genetic libraries in S. pombe?

Repurposing SPAC144.01 Antibody for genetic library screening requires careful method development. First, establish a high-throughput detection system – either automated Western blotting platforms or ELISA in 384-well format – optimizing antibody concentration to maximize sensitivity while minimizing reagent usage. Second, develop a robust scoring system that accounts for variable expression levels across mutant libraries, potentially using internal controls and Z-score normalization. Third, validate screening hits with orthogonal methods, as polyclonal antibodies may occasionally recognize proteins other than the intended target. Fourth, consider epitope accessibility in different genetic backgrounds, as mutations affecting protein folding or interaction partners may mask the antibody binding site without affecting protein expression. Fifth, implement appropriate statistical methods for hit identification, including false discovery rate controls and replicate consistency thresholds. When screening gene deletion libraries, include wild-type and known SPAC144.01-related mutants as controls in each plate. For overexpression libraries, carefully calibrate detection to accommodate the wide dynamic range of protein expression. Finally, develop secondary screens using functional assays to distinguish biologically relevant hits from technical artifacts .